Pharmacokinetic evaluation of polymeric carriers

Advanced Drug Delivery Reviews

Volumn 21, Issue 2, 1996, Pages 135-155

  Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

biodistribution; carbohydrate recognition; chemical modification; drug targeting index; macromolecular drug carrier; pharmacokinetics; physicochemical characteristics; targeting efficiency; tumor targeting

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; MACROMOLECULES; MOLECULAR WEIGHT; MONOCLONAL ANTIBODIES; PHARMACOKINETICS; PHYSIOLOGY; POLYMERS;

CARBOHYDRATE RECEPTOR GLYCOSYLATED MACROMOLECULE; FLUID PHASE ENDOCYTOSIS RATE; GLOMENULAR FILTRATION RATE; HEPATIC UPTAKE CLEARANCE; PLASMA FLOW RATE; POLYMERIC CARRIERS;

CONTROLLED DRUG DELIVERY;

ANION; BOVINE SERUM ALBUMIN; CARBOXYMETHYLDEXTRAN; CATION; DEXTRAN; DIETHYLAMINOETHYLDEXTRAN; DRUG CARRIER; INDIUM 111; IODINE 125; LYSOZYME; MITOMYCIN C; MITOMYCIN C DERIVATIVE; PENTETATE INDIUM IN 111; POLYLYSINE; POLYMER; RECOMBINANT SUPEROXIDE DISMUTASE; SOYBEAN TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; ZINOSTATIN;

ANTIGEN ANTIBODY REACTION; CHEMICAL MODIFICATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG TARGETING; LIVER; MACROMOLECULE; MODEL; MOLECULAR WEIGHT; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; THEORY; TUMOR; URINARY EXCRETION;

EID: 0030590447     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00403-6     Document Type: Review

References (137)

1. [1] Crone, C. and Levitt, D.G. (1984) Capillary permeability to small solutes. In: E.M. Renkin and C.C. Michel (Eds), Handbook of Physiology: The Cardiovascular System IV, American Physiological Society, Bethesda, pp. 411-466.
2. [2] Sezaki, H. and Hashida, M. (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Systems 1, 1-38.
3. [3] Sezaki, H., Takakura, Y. and Hashida, M. (1989) Soluble macromolecular carriers for the delivery of antitumor drugs. Adv. Drug Deliv. Rev. 3, 247-266.
4. [4] Larsen, C. (1989) Dextran prodrugs - structure and stability in relation to therapeutic activity. Adv. Drug Deliv. Rev. 3, 103-154.
5. [5] Hashida, M. and Takakura, Y. (1994) Pharmacokinetics in design of polymeric drug delivery systems. J. Control. Release 31, 163-171.
6. [6] Takakura, Y. and Hashida, M. (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18, 207-231.
7. [7] Simionescu, N. (1983) Cellular aspects of transcapillary exchange. Physiol. Rev. 63, 1536-1579.
8. [8] Taylor, A.E. and Granger, D.N. (1984) Exchange of macromolecules across the microcirculation. In: E.M. Renkin and C.C. Michel (Eds), Handbook of Physiology: The Cardiovascular System IV, American Physiological Society, Bethesda, pp. 467-520.
9. [9] Jain, R.K. (1987) Transport of molecules across tumor vasculature. Cancer Metas. Rev. 6, 559-593.
10. [10] Jain, R.K. (1988) Determinants of tumor blood flow: a review. Cancer Res. 48, 2641-2658.
11. [11] Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D.A., Torchilin, V.P. and Jain, R.K. (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756.
12. [12] O'Connor, S.W. and Bale, W.F. (1984) Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. Cancer Res. 44, 3719-3723.
13. [13] Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
14. [14] Takakura, Y., Takagi, A., Hashida, M. and Sezaki, H. (1987) Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4, 293-300.
15. [15] Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Systems 6, 193-210.
16. [16] Takakura, Y., Fujita, T., Hashida, M. and Sezaki, H. (1990) Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7, 339-346.
17. [17] Seymour, L.W. (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Systems 9, 135-187.
18. [18] Bernstein, A., Hurwitz, E., Maron, R., Arnon, R., Sera, M. and Wilchek, M. (1978) Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J. Natl. Cancer Inst. 60, 379-384.
19. [19] Hashida, M., Kato, A. and Kojima, T. (1981) Antitumor activity of mitomycin C-dextran conjugate against various murine tumors. Gann 72, 226-234.
20. [20] Levy-Schaffer, F., Bernstein, A., Meshorer, A. and Arnon, R. (1982) Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat. Rep. 66, 107-114.
21. [21] Takakura, Y., Matsumoto, S., Hashida, M. and Sezaki, H. (1984) Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res. 44, 2505-2510.
22. [22] Takakura, Y., Kitajima, M., Matsumoto, S., Hashida, M. and Sezaki, H. (1987) Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities. Int. J. Pharm. 37, 135-143.
23. [23] Takakura, Y., Atsumi, R., Hashida, M. and Sezaki, H. (1987) Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular injection. Int. J. Pharm. 37, 145-154.
24. [24] Kaneo, Y., Fujihara, Y., Tanaka, T., Kozawa, Y., Mori, H. and Iguchi, S. (1989) Intrahepatic delivery of glutathione by conjugation to dextran. Pharm. Res. 6, 1025-1031.
25. [25] Zunino, F., Giuliani, F., Savi, G., Dasdia, T. and Gambetta, R. (1982) Antitumor activity of daunorubicin conjugated to antitumor antibodies. Cancer Res. 35, 1182-1186.
26. [26] Roos, C.F., Matsumoto, S., Takakura, Y., Hashida, M. and Sezaki, H. (1984) Physicochemical and antitumor characteristics of some polyamino acid prodrugs of mitomycin C. Int. J. Pharm. 22, 75-87.
27. [27] Morimoto, Y., Sugibayashi, K., Sugihara, S., Hosoya, S., Nozaki, S. and Ogawa, Y. (1984) Antitumor agent poly (amino acid) conjugates as a drug carrier in cancer chemotherapy. J. Pharmacobio-Dyn. 7, 688-698.
28. [28] Hoes, C.J.T., Potman, W. and Van Heeswijk, W.A.R. (1985) Optimisation of macromolecular prodrugs of the antitumor antibiotic adriamycin. J. Control. Release 2, 205-218.
29. [29] Schechther, B., Wilcheck, M. and Srnon, R. (1987) Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic acid against a murine carcinoma. Int. J. Cancer 39, 409-413.
30. [30] Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I.C., Lloyd, J.B. and Kopecek, J. (1988) Anti-cancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br. J. Cancer 57, 147-156.
31. [31] Cassidy, J., Duncan, R., Morrison, G.J., Strohalm, J., Kopecek, J. and Kaye, S.B. (1989) Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumor model. Biochem. Pharmacol. 38, 875-879.
32. [32] Seymour, L.W., Ulbrich, K., Strohalm, J., Kopecek, J. and Duncan, R. (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39, 1125-1131.
33. [33] Duncan, R., Hume, I.C., Yardley, H.Y., Flanagan, P.A., Ulbrich, K., Subr, V. and Strohalm, J. (1991) Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Control. Release 16, 121-136.
34. [34] Seymour, L.W., Ulbrich, K., Steyger, P.S., Brereton, M., Subr, V., Strohalm, J. and Duncan, R. (1994) Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636-641.
35. [35] Yamaoka, T., Tabata, Y. and Ikada, Y. (1995) Fate of water-soluble polymers administered via different routes. J. Pharm. Sci. 84, 349-354.
36. [36] Seymour, L.W., Miyamato, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K. and Duncan, R. (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31, 766-770.
37. [37] Takakura, Y., Mahato, R.I., Nishikawa, M. and Hashida, M. (1996) Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv. Drug Deliv. Rev. 19, 377-399.
38. [38] Jain, R.K. (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81, 570-576.
39. [39] Juweid, M., Neumann, R., Paik, C., Perez-Bacete, M.J., Sato, J., van Osdol, W. and Weinstein, J.N. (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144-5153.
40. [40] Reilly, R.M., Sandhu, J., Alvares-Diez, T.M., Gallinger, S., Kirsh, J. and Stern, H. (1995) Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet. 28, 126-142.
41. [41] Fiume, L., Bassi, B., Busi, C., Mattioli, A., Spinosa, G. and Faulstich, H. (1986) Galactosylated poly(L-lysine) as a hepatotropic carrier of 9-(β-D-arabinofuranosyladenine 5′-monophosphate. Fed. Eur. Biochem. Soc. Lett. 203, 203-206.
42. [42] Chakraborty, P., Bhaduri, A.N. and Das, P.K. (1990) Neoglycoproteins as carriers for receptor-mediated drug targeting in the treatment of experimental visceral leishmaniasis. J. Protozool. 37, 358-364.
43. [43] Nishikawa, M., Kamijo, A., Fujita, T., Takakura, Y., Sezaki, H. and Hashida, M. (1993) Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm. Res. 10, 1253-1261.
44. [44] Franssen, E.J., Jansen, R.W., Vaalburg, M. and Meijer, D.K.F. (1993) Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem. Pharmacol. 45, 1215-1226.
45. [45] Fiume, L., Di Stefano, G., Busi, C. and Mattioli, A. (1994) A conjugate of lactosaminated poly-L-lysine with adenosine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver. Biochem. Pharmacol. 47, 643-650.
46. [46] Hashida, M., Nishikawa, M. and Takakura, Y. (1995) Hepatic targeting of drugs and proteins by chemical modification. J. Control. Release 36, 99-107.
47. [47] Hirabayashi, H., Nishikawa, M., Takakura, Y. and Hashida, M. (1996) Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharm. Res. 13, 880-884.
48. [48] Hashida, M., Hirabayashi, H., Nishikawa, M. and Takakura, Y. (1996) Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. J. Control. Release in press.
49. [49] Fujita, T., Nishikawa, M., Tamaki, C., Takakura, Y., Hashida, M. and Sezaki, H. (1992) Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono-and poly-saccharide derivatives. J. Pharmacol. Exp. Ther. 263, 971-978.
50. [50] Fujita, T., Furitsu, H., Nishikawa, M., Takakura, Y., Sezaki, H. and Hashida, M. (1992) Therapeutic effects of superoxide dismutase derivatives modified with mono-or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem. Biophys. Res. Commun. 189, 191-196.
51. [51] Hashida, M., Nishikawa, M., Yamashita, F. and Takakura, Y. (1994) Targeting delivery of protein drugs by chemical modification. Drug Dev. Ind. Pharm. 20, 581-590.
52. [52] Nishikawa, M., Hirabayashi, H., Takakura, Y. and Hashida, M. (1995) Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficacy. Pharm. Res. 12, 209-214.
53. [53] Wu, G.Y. and Wu, C.H. (1988) Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263, 14 621-14 624.
54. [54] Chowdhury, N.R., Wu, C.H., Wu, G.Y., Yerneni, P.C., Bommineni, V.R. and Chowdhury, J.R. (1993) Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo: prolonged persistence in cytoplasmic vesicles after partial hepatectomy. J. Biol. Chem. 268, 11 265-11 271.
55. [55] Perales, J.C., Ferkol, T., Beegen, H., Ratnoff, O.D. and Hanson, R.W. (1994) Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA 91, 4086-4090.
56. [56] Lu, X.M., Fischman, A.J., Jyawook, S.L., Hendricks, K., Tompkins, R.G. and Yarmush, M.L. (1994) Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nucl. Med. 35, 269-275.
57. [57] Krants, M.J., Holtzman, N.A., Stowell, C.P. and Lee, Y.C. (1976) Attachment of thioglycosides to proteins: enhancement of liver membrane binding. Biochemistry 15, 3963-3968.
58. [58] Connolly, D.T., Townsend, R.R., Kawaguchi, K., Hobish, M.K., Bell, W.R. and Lee, Y.C. (1983) Binding and endocytosis of glycoproteins and neoglycoproteins by isolated rabbit hepatocytes. Biochem. J. 214, 421-431.
59. [59] Vera, D.R., Krohn, K.A., Stadalnik, R.C. and Scheibe, P.O. (1984) Tc-99m-galactosyl-neoglycoalbumin: in vivo characterization of receptor-mediated binding to hepatocytes. Radiology 151, 191-196.
60. [60] Nishikawa, M., Ohtsubo, Y., Ohno, J., Fujita, T., Koyama, Y., Yamashita, F., Hashida, M. and Sezaki, H. (1992) Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. Int. J. Pharm. 85, 75-85.
61. [61] Morell, A.G., Irvine, R.A., Sternlieb, I., Scheinberg, H. and Ashwell, G. (1968) Physical and chemical studies on ceruloplasmin. V: metabolic studies on sialic acid-free ceruloplasmin in vivo. J. Biol. Chem. 243, 155-159.
62. [62] Morell, A. G., Gregoriadis, G., Scheinberg, H., Hickman, J, and Ashwell, G. (1971) The role of sialic acid in determining the survival of glycoproteins in the circulation. J. Biol. Chem. 246, 1461-1467.
63. [63] Goldwasser, E., Kung, C.J.K. and Eliason, J. (1974) On the mechanism of erythropoietin-induced differentiation. XIII: the role of sialic acid in erythropoietin action. J. Biol. Chem. 249, 4202-4206.
64. [64] Bose, S. and Hickman, J. (1977) Role of carbohydrate moiety in determining the survival of interferon in the circulation. J. Biol. Chem. 252, 8336-8337.
65. [65] Regoeczi, E., Debanne, M.T., Hatton, M.C. and Koj, A. (1978) Elimination of asialofetuin and asialoorosomucoid by the intact rat. Quantitative aspects of the hepatic clearance mechanism. Biochim. Biophys. Acta 541, 372-384.
66. [66] Hnatowich, D.J., Layne, W.W., Childs, R.L., Lanteigne, D., Davis, M.A. and Griffin, T.W. (1983) Radioactive labeling of antibody: a simple and efficient method. Science 220, 613-615.
67. [67] Khaw, B.A., Cooney, J., Edgington, T. and Strauss, H.W. (1986) Differences in experimental tumor localization of dual-labeled monoclonal antibody. J. Nucl. Med. 27, 1293-1299.
68. 111In. Cancer Res. 47, 1149-1154.
69. [69] Arano, Y., Mukai, T., Uezono, T., Wakisaka, K., Motonari, H., Akizawa, H., Taoka, Y. and Yokoyama, A. (1994) A biological method to evaluate bifunctional chelating agents to label antibodies with metallic radionuclides. J. Nucl. Med. 35, 890-898.
70. [70] Duncan, J.R. and Welch, M.J. (1993) Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J. Nucl. Med. 34, 1728-1738.
71. [71] Arano, Y. (1995) Antibody-associated chelates for targeted imaging. In: V.P. Torchilin (Ed.), Handbook of Targeted Delivery of Imaging Agents, CRC Press, Boca Raton, pp. 103-117.
72. [72] Ali, S.A., Eary, J.F., Warren, S.D., Badger, C.C. and Krohn, K.A. (1988) Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies. Nucl. Med. Biol. 15, 557-561.
73. 125I-tyramine) and autoradiography. Cancer Immunol. Immunother. 33, 359-366.
74. [74] Thorpe, S.R., Baynes, J.W. and Chroneos, Z.C. (1993) The design and application of residualizing labels for studies of protein catabolism. Fed. Am. Soc. Exp. Biol. J. 7, 399-405.
75. [75] Carney, P.L., Rogers, P.E. and Johnson, D.K. (1989) Dual isotope study of iodine-125 and indium-111-labeled antibody in athymic mice. J. Nucl. Med. 30, 374-384.
76. [76] Deshpande, S.V., Subramanian, R., McCall, M.J., DeNardo, S.J., DeNardo, G.L. and Meares, C.F. (1990) Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. J. Nucl. Med. 31, 218-224.
77. [77] Gansow, O.A. (1991) Newer approaches to the radio-labeling of monoclonal antibodies by use of metal chelates. Nucl. Med. Biol. 18, 369-381.
78. [78] Mowry, R.W. and Millican, C.M. (1953) A histochemical study of the distribution and fate of dextran in tissues of the mouse. Am. J. Pathol. 29, 523-540.
79. 2 to soluble dextrans. II. In vivo distribution and fate of conjugates. Biochem. Pharmacol. 36, 113-121.
80. [80] Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T. (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4, 879-885.
81. [81] Takakura, Y., Fujita, T., Furitsu, H., Nishikawa, M., Sezaki, H. and Hashida, M. (1994) Pharmacokinetics of succinylated proteins and dextran sulfate in mice: implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptor. Int. J. Pharm. 105, 19-29.
82. [82] Adolph, E.F. (1949) Quantitative relations in the physiological constitutions of mammals. Science 109, 579-585.
83. [83] Hackbarth, H., Büttner, D. and Gärtner, K. (1982) Intraspecies allometry: correlation between kidney weight and glomerular filtration rate vs. body weight. Am. J. Physiol. 242, R303-R305.
84. [84] Brenner, B.M., Hostetter, T.H. and Humes, H.D. (1978) Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Am. J. Physiol. 234, F455-F460.
85. [85] Maack, T., Johnson, V., Kau, S.T., Figueiredo, J. and Sigulem, D. (1979) Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16, 251-270.
86. [86] Mihara, K., Mori, M., Hojo, T., Takakura, Y., Sezaki, H. and Hashida, M. (1993) Disposition characteristics of model macromolecules in the perfused rat kidney. Biol. Pharm. Bull. 16, 158-162.
87. [87] Mihara, K., Hojo, T., Fujikawa, M., Takakura, Y., Sezaki, H. and Hashida, M. (1993) Disposition characteristics of protein drugs in the perfused rat kidney. Pharm. Res. 10, 823-827.
88. [88] Takakura, Y., Mihara, K. and Hashida, M. (1994) Control of the disposition profiles of proteins in the kidney via chemical modification. J. Control. Release 28, 111-119.
89. [89] Pardridge, W.M., Kumagai, A.K. and Eisenberg, J.B. (1987) Chimeric peptides as a vehicle for peptide pharmacokinetical delivery through the blood-brain barrier. Biochem. Biophys. Res. Commun. 146, 307-313.
90. [90] Fujita, T., Nishikawa, M., Ohtsubo, Y., Ohno, J., Takakura, Y., Sezaki, H. and Hashida, M. (1994) Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J. Drug Targeting 2, 157-165.
91. [91] Fujita, T., Takakura, Y., Sezaki, H. and Hashida, M. (1995) Control of disposition characteristics of proteins by direct cationization in mice. Pharm. Sci. 1. 371-375.
92. [92] Meijer, D.K.F. and van der Sluijs, P. (1989) Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery. Pharm. Res. 6, 105-118.
93. [93] Bu, G. and Schwartz, A.L. (1994) Receptor-mediated endocytosis. In: I.M. Arias, J.L. Boyer, N. Fausto, W.B. Jakoby, D.A. Schachter and D.A. Schafritz (Eds), The Liver: Biology and Pathobiology, Third Edition, Raven Press, Ltd., New York, pp. 259-274.
94. [94] Kuiper, J., Brouwer, A., Knook, D.L. and van Berkel T.J.C. (1994) Kupffer and sinusoidal endothelial cells. In: I.M. Arias, J.L. Boyer, N. Fausto, W.B. Jakoby, D.A. Schachter and D.A. Schafritz (Eds), The Liver: Biology and Pathobiology, Third Edition, Raven Press, Ltd., New York, pp. 791-818.
95. 125I-labelled poly(vinylpyrrolidone) in vivo. Biochem. J. 192, 613-621.
96. [96] Nakane, S., Matsumoto, S., Takakura, Y., Hashida, M. and Sezaki, H. (1988) The accumulation mechanism of cationic mitomycin C-dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes. J. Pharm. Pharmacol. 40, 1-6.
97. [97] Nishida, K., Tonegawa, C., Nakane, S., Takakura, Y., Hashida, M. and Sezaki, H. (1990) Effect of electric charge on the hepatic uptake of macromolecules in the rat liver. Int. J. Pharm. 65, 7-17.
98. [98] Nishida, K., Mihara, K., Takino, T., Nakane, S., Takakura, Y., Hashida, M. and Sezaki, H. (1991) Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 8, 437-443.
99. [99] Gerlowski, L.E. and Jain, R.K. (1983) Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72, 1103-1127.
100. [100] Krieger, M., Acton, S., Ashkenas, J., Peason, A., Penman, M. and Resnick, D. (1993) Molecular flypaper, host defence and atherosclerosis: structure, binding properties and functions of macrophage scavenger receptors. J. Biol. Chem. 268, 4569-4572.
101. [101] Kawabata, K., Takakura, Y. and Hashida, M. (1995) The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12, 825-830.
102. [102] Yoshida, M., Mahato, R.I., Kawabata, K., Takakura, Y. and Hashida, M. (1996) Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharm. Res. 13, 599-603.
103. [103] Kojima, J., Hashida, M., Muranishi, S. and Sezaki, H. (1980) Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C. J. Pharm. Pharmacol. 32, 30-34.
104. [104] Hashida, M., Kato, A., Kojima, T., Muranishi, S., Sezaki, H., Tanigawa, N., Satomura, K. and Hikasa, Y. (1981) Antitumor activity of mitomycin C-dextran conjugate against various murine tumors. Gann 72, 226-234.
105. [105] Kato, A., Takakura, Y., Hashida, M., Kimura, T. and Sezaki, H. (1982) Physico-chemical and antitumor characteristics of high molecular weight prodrugs of mitomycin C. Chem. Pharm. Bull. 30, 2951-2957.
106. [106] Matsumoto, S., Arasc, Y., Takakura, Y., Hashida, M. and Sezaki, H. (1985) Plasma disposition and in vivo and in vitro antitumor activities of mitomycin C dextran conjugate in relation to the mode of action. Chem. Pharm. Bull. 33, 2941-2947.
107. [107] Takakura, Y., Matsumoto, S., Hashida, M. and Sezaki. H. (1989) Physicochemical properties and antitumor activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control. Release 10, 97-105.
108. [108] Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Takakura, Y., Hashida, M. and Sezaki, H. (1991) Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Jpn. J. Cancer Res. 82, 219-226.
109. [109] Schwartz, H.S. and Philips, F.S. (1961) Pharmacology of mitomycin C. II. Renal excretion and metabolism by tissue homogenates. J. Pharmacol. Exp. Ther. 133, 335-342.
110. [110] Imoto, H., Sakamura, Y., Ohkouchi, K., Atsumi, R., Takakura, Y., Sezaki, H. and Hashida, M. (1992) Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation. Cancer Res. 52, 4396-4401.
111. [111] Matsumoto, S., Yamamoto, A., Takakura, Y., Hashida, M., Tanigawa, N. and Sezaki, H. (1986) Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate. Cancer Res. 46, 4463-4468.
112. [112] Roche, A.C., Barzilay, M., Midoux, P., Junqua, S., Sharon, N. and Monsigny, M. (1983) Sugar-specific endocytosis of glycoproteins by Lewis lung carcinoma cells. J. Cell. Biochem. 22, 131-140.
113. [113] Gabius, H.J. (1987) Targeting of neoglycoprotein-drug conjugates to human tumor cells via endogenous lectins. In: R.L. Juliano (Ed.), Biological Approaches to the Controlled Delivery of Drugs. Vol. 507, The New York Academy of Sciences, New York, pp. 337-338.
114. 4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. Biochem. Pharmacol. 40, 2603-2610.
115. [115] Gonsho, A., Irie, K., Susaki, H., Iwasawa, H., Okuno, S. and Sugawara, T. (1994) Tissue-targeting ability of saccharide-poly(L-lysine) conjugates. Biol. Pharm. Bull. 17, 275-282.
116. [116] Ashwell, G. and Harford, J. (1982) Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51, 531-554.
117. [117] Fiume, L., Mattioli, A., Balboni, P.G., Tognon, M., Barbanti-Brodano, G., De Vries, J. and Wieland, T. (1979) Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. Fed. Eur. Biochem. Soc. Lett. 103. 47-51.
118. [118] Fiume, L., Mattioli, A., Buci, C., Balboni, P.G., Barbanti-Brodano, G., De Vries, J., Altmann, R. and Wieland, T. (1980) Selective inhibition of Ectromelia virus DNA synthesis in hepatocytes by adenine-9-β-D-arabinofuranoside (ara-A) and adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) conjugated to asialofetuin. Fed. Eur. Biochem. Soc. Lett. 116, 185-188.
119. [119] Lee, Y.C., Townsend, R.R., Hardy, M.R., Lönngren, J., Arnarp, J., Haraldsson, M. and Lönn, H. (1983) Binding of synthetic oligosaccharides to the hepatic Gal/ GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 258, 199-202.
120. [120] Townsend, R.R., Hardy, M.R., Wong, T.C. and Lee, Y.C. (1986) Binding of N-linked bovine fetuin glycopeptides to isolated rabbit hepatocytes: Gal/GalNAc hepatic lectin discrimination between Galβ(1,4)-GalNAc and Galβ(1,3)GalNAc in a triantennary structure. Biochemistry 25, 5716-5725.
121. [121] Vera, D.R., Krohn, K.A., Stadalnik, R.C. and Scheibe, P.O. (1984) Tc-99m-galactosyl-neoglycoalbumin: In vitro characterization of receptor-mediated binding. J. Nucl. Med. 25, 779-787.
122. [122] Bischoff, K.B., Dedrick, R.L., Zaharko, D.S. and Longstreth, J.A. (1971) Methotrexate pharmacokinetics. J. Pharm. Sci. 60, 1128-1133.
123. [123] Gibaldi, M. and Perrier, D. (1975) Pharmacokinetics, Marcel Dekker, Inc., New York.
124. [124] Nishikawa, M., Miyazaki, C., Yamashita, F., Takakura, Y. and Hashida, M. (1995) Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. Am. J. Physiol. 268, G849-G856.
125. [125] Yamaoka, K. and Nakagawa, T. (1983) A nonlinear least squares program based on differential equations, MULTI(RUNGE), for microcomputers. J. Pharmacobio-Dyn. 6, 595-606.
126. [126] Nishikawa, M., Yamashita, F., Takakura, Y., Hashida, M. and Sezaki, H. (1992) Demonstration of the receptor-mediated hepatic uptake of dextran in mice. J. Pharm. Pharmacol. 44, 396-401.
127. [127] Shockley, T.R., Lin, K., Sung, C., Nagy, J.A., Tompkins, R.G., Dedrick, R.L., Dvorak, H.F. and Yarmush, M.L. (1992) A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res. 52, 357-366.
128. [128] Juweid, M., Neumann, R., Paik, C., Perez-Bacete, M.J., Sato, J., van Osdol, W. and Weinstein, J.N. (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144-5153.
129. [129] Baxter, L.T., Zhu, H., Mackensen, D.G. and Jain, R.K. (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human xenografts in nude mice. Cancer Res. 54, 1517-1528.
130. [130] Yilla, M. and Doyle, D. (1994) Plasma membrane: biogenesis and turnover. In: I.M. Arias. J.L. Boyer, N. Fausto, W.B. Jakoby, D.A. Schachter and D.A. Schafritz (Eds), The Liver: Biology and Pathobiology, Third Edition, Raven Press, Ltd., New York, pp. 155-177.
131. [131] Sung, C., Shockley, T.R., Morrison, P.F., Dvorak, H.F., Yarmush, M.L. and Dedrick, R.L. (1992) Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 52, 377-384.
132. [132] van Osdol, W., Fujimori, K. and Weinstein, J.N. (1991) An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a 'binding site barrier' Cancer Res. 51, 4776-4784.
133. [133] Saga, T., Neumann, R.D., Heya, T., Sato, J., Kinuya, S., Le, N., Paik, C.H. and Weinstein, J.N. (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding site barrier. Proc. Natl. Acad. Sci. USA 92, 8999-9003.
134. [134] Hunt, C.A., MacGregor, R.D. and Siegel, R.A. (1986) Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm. Res. 3, 333-344.
135. [135] Stella, V.J. and Himmelstein, K.J. (1985) Prodrugs: a chemical approach to targeted drug delivery. In: R.T. Borchardt, A.J. Repta and V.J. Stella (Eds), Directed Drug Delivery, Humana Press, Clifton, pp. 247-267.
136. [136] Bodor, N., Farag, H.H. and Brewster, M.E. (1983) Redox delivery for brain specific, sustained release of dopamine. Science 221, 65-67.
137. [137] Levy, G. (1987) Targeted drug delivery - some pharmacokinetic considerations. Pharm. Res. 4, 3-4.